
Construction of drug development platform of disease-specific degradation by CANDDY (FuturedMe Inc.)



City	Year of Establishment	Founder	Website
Chuou-ku,Tokyo	2018	Etsuko Miyamoto-Sato	https://futuredme. com/jp/#secMV

Partner VC	Latest round of Fundraising	Valuation
KSP,Inc.	Series A	Non-Disclosure

Contact Information :

tel: 81-4-7197-6230

Website : <u>https://futuredme.com/jp/#secMV</u>

\bigcirc Business Plan

In the era of precision medicine, genomic medicine needs to solve the problem (pain) that even if the causative molecule (target) of a disease is identified, there is no therapeutic drug for the target. To this end, we will raise the barrier to entry for CANDDY, the next-generation degradative drug discovery technology, and build a disease-specific degradative drug development platform that will establish a differentiated prototype, expand the market, and reduce side effects.

\bigcirc Research Outline

In this research and development, we will construct the "Immune CANDDY Platform" as a degradative drug development technology that does not act on normal cells but can target degradation only in cancer cells due to immunoproteasome selectivity.

Shows the difference in the degradation index (DC50) between normal cells and diseased cells.
Shows the degradation of naturally denatured proteins.
Showing the POC of the initial prototype of the CANDDY molecule.

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	STS 2023~2025FY	JPY 61 million	Worldwide, especially in the US

OInternational collaborative technology demonstration

Contract with local partners

STS phase plans to have a Japanese pharmaceutical company become an expert and obtain a "letter of interest" from PCA phase to realize a partnership. We will also be in contact with pharmaceutical companies in the United States or Europe etc., and plan to partner with overseas pharmaceutical companies after graduation.

As of February, 2024